Xcout Intelステムセル研究所 competitors & alternatives
The 12 closest competitors and alternatives to ステムセル研究所 among biotech companies — ranked by similarity to what ステムセル研究所 actually does, not by market-cap band.
Subscribe to see ステムセル研究所’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ステムセル研究所
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.
ステムセル研究所 at a glance
ステムセル研究所 is a biotech company headquartered in Tokyo, Japan, founded in 1999. It is publicly listed (7096) with a market capitalisation of $47.9M.
Top 12 ステムセル研究所 competitors
Ranked by semantic similarity — how close each company is to ステムセル研究所 by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
PBKM is a leading European stem cell bank that provides services for the collection and storage of umbilical cord blood and other biological materials.
Similar biotech company
Medipost Co., Ltd. is a South Korean biotechnology company developing and commercializing stem-cell-based regenerative medicines, including treatments derived from human umbilical cord blood mesenchymal stem cells. It also operates a cord-blood banking business serving expectant parents and families.
Similar biotech company
Yubo International Biotech Limited, operating through its various subsidiaries, primarily dedicates its efforts to the research, development, and practical application of endometrial stem cells. Beyond this core focus, the company also provides a diverse range of products, including solutions for respiratory health, skincare and hair care formulations, nutritious beverages, and personal care items tailored for both men and women. Furthermore, it delivers specialized stem cell services, such as cellular analysis and comprehensive health management consulting, all offered under the VIVCELL brand. The company's headquarters are located in Beijing, China.
Biotechnology
Junten Bio Co. Ltd. is a Japanese pharmaceutical and biotechnology corporation headquartered in Tokyo, specializing in the research and development of cell and regenerative medicine.
Biotechnology
Cell Research Corporation is a biotechnology company specializing in umbilical cord lining stem cell technology and banking. The company provides products, services, and contract research related to stem cell applications for wound healing, regenerative medicine, and cosmeceuticals.
Similar biotech company
Vcanbio Cell & Gene Engineering Corp., Ltd, established in 1992 and headquartered in Tianjin, China, primarily focuses on providing cell preparation and cryopreservation services across the People's Republic of China. The company's offerings include the handling and storage of a diverse array of stem cells, such as hematopoietic stem cells derived from umbilical cord blood, umbilical cord mesenchymal stem cells, placental sub-totipotent stem cells, adipose stem cells, and dental stem cells, alongside immune cells. Beyond its core cell banking operations, Vcanbio delivers a spectrum of genetic testing services. These include non-invasive prenatal screening, pharmacogenomic testing for safe medication guidance in both adults and children, and analyses for disease genetics and susceptibility. Additionally, the company supplies essential raw materials for in vitro diagnostics, specifically monoclonal and polyclonal antibodies. Vcanbio is also actively involved in the research, development, manufacturing, and commercialization of various biological products, including genes, proteins, and antibodies, as well as pharmaceutical intermediates, experimental synthetic agents, in vitro diagnostic reagents, and medical devices.
Biotechnology
Cellect Biotechnology Ltd. was an Israeli biotechnology company developing cell-selection and regenerative-medicine technologies, including its ApoGraft platform for enriching stem cells from bone marrow or other cell sources. Its products were intended primarily for clinical and research applications involving hematopoietic stem-cell transplantation and cell-based therapies.
Biotechnology
Restore Vision Inc. is a Japanese startup headquartered in Tokyo that aims to develop visual restoration gene therapies.
Similar biotech company
Conception Holdings, Inc. develops stem cell technology and computational platforms to generate functional human eggs in the lab through in-vitro gametogenesis. The company aims to expand reproductive options for individuals facing biological and medical fertility limits by recreating key steps of human development.
Biotechnology
NutrigeneAI Biotech Limited is an iPSC cell therapy platform operating in Hong Kong. The company focuses on biotechnology research and development, maintaining pipeline therapies and regional office operations.
Similar biotech company
AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmid, an innovative gene therapy designed to address critical limb ischemia, a severe circulatory condition impacting the legs. The company's diverse pipeline also includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine formulated to suppress inflammation for various ailments, including low back pain. Furthermore, AnGes is actively developing treatments for atopic dermatitis and disc degeneration, as well as specialized medical devices aimed at preventing vascular restenosis. Their development endeavors also extend to therapeutic vaccines for cervical intraepithelial neoplasia, a precursor to cervical cancer, and, through a research partnership with Osaka University, DNA vaccines targeting hypertension. AnGes fosters strategic alliances to expand its global reach and product commercialization. These collaborations include BioMarin Pharmaceutical Inc. for the Japanese market distribution of Naglazyme, a drug for mucopolysaccharidosis VI; and Mitsubishi Tanabe Pharma Corporation, which handles the marketing of HGF Plasmid for peripheral arterial disease in both the United States and Japan. Other key partners are SHIONOGI & CO., LTD. for the commercialization of topical NF-kB decoy oligonucleotide drugs for dermatological conditions, and Vical, Inc. for the development and marketing of Allovectin, a cancer treatment. Additionally, AnGes has joined forces with Osaka University to develop a coronavirus vaccine, and with Brickell Biotech, Inc. for an investigational plasmid DNA vaccine intended to prevent coronavirus across the U.S., South America, and other territories. The company, previously known as AnGes MG, Inc., officially rebranded to AnGes, Inc. in July 2017.
Similar biotech company
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ステムセル研究所 and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ステムセル研究所and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →